Regulations
Description:
This handout discusses how a prescribing physician may prepare for a visit from the DEA. Such visits are required by law for physicians prescribing buprenorphine, and involve things such as prescription and dispensing records, and adherence to prescribing limits on number of patients.
Source:
PCSS
Tags:
Description:
This clinical guidance provides information about the requirements for storing, dispensing, and maintaining records for physicians who provide office-based opioid treatment.
Source:
Physician Clinical Support System (PCSS)
Tags:
Description:
Informational checklist designed to aid health care providers in making sure their practice is compliant with HIPAA regulations.
Source:
Substance Abuse and Mental Health Services Administration (SAMHSA) (3 votes)
Tags:
Description:
This form is for physicians to notify the DEA (through the Substance Abuse and Mental Health Services Administration) of their intent to use Schedule III, IV, or V drugs for treatment of opioid dependent patients.
Source:
The National Alliance of Advocates for Buprenorphine Treatment (NAABT) (3 votes)
Tags:
Description:
This report by SAMHSA addresses the issues of buprenorphine diversion and abuse of which have developed in recent years. The report gives a summary of the findings on diversion and abuse and recommendations for the future.
Source:
Substance Abuse and Mental Health Services Administration (SAMHSA) (3 votes)
Tags:
Description:
Manual written by the DEA to assist physicians in understanding and complying with the Federal Controlled Substances Act. Topics covered include recordkeeping requirements, rules regarding prescription, and security requirements.
Source:
US Drug Enforcement Administration (DEA) (3 votes)
Tags:
Description:
Guidance on the legal rights of individuals with alcohol and drug problems to help patients understand how they are protected from discrimination.
Source:
The National Alliance of Advocates for Buprenorphine Treatment (NAABT) (2 votes)
Tags:
